SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02299622

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Establishment of Personalized Cancer Medicine Using Samsung Cancer Sequencing Platform in Lung Cancer/Mediastinal Tumor/ Head & Neck/Esophageal Cancer/Rare Cancer (PerSeq: Personalized Sequence)

The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly. The genome analysis needs systematic infra and database based on personal genetic information Therefore, a big data of genome-clinical information is important.

NCT02299622 Lung Cancer
MeSH:Lung Neoplasms
HPO:Neoplasm of the lung

1 Interventions

Name: Genetic test

Description: Next-generation sequencing (AmpliSeq) & fusion analysis
Type: Genetic


Primary Outcomes

Description: The pattern of the tumor's molecular profiling in advanced thoracic (lung, esophagus, or tthymic) cancer

Measure: the spectrum of targetable genetic mutation in evaluated cancer specimens (for example, % of EGFR T790M mutation, BRAF mutation, or ALK mutation)

Time: 3 years

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 T790M

the spectrum of targetable genetic mutation in evaluated cancer specimens (for example, % of EGFR T790M mutation, BRAF mutation, or ALK mutation). --- T790M ---



HPO Nodes


HPO: